Withdrawal from chronic administration of cocaine decreases delta opioid receptor signaling and increases anxiety- and depression-like behaviors in the rat

Neuropharmacology

Volumn 54, Issue 2, 2008, Pages 355-364

  Perrine, Shane A ^a   Sheikh, Imran S ^a   Nwaneshiudu, Chinwe A ^a   Schroeder, Joseph A ^a   Unterwald, Ellen M ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Adenylyl cyclase; Anxiety; Cocaine; Delta opioid receptor; Depression; Rat; SNC80

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; DELTA OPIATE RECEPTOR AGONIST; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME;

ADENYLATE CYCLASE; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BENZAMIDES; COCAINE; DATA INTERPRETATION, STATISTICAL; DEPRESSION; MALE; MOTOR ACTIVITY; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, DELTA; SIGNAL TRANSDUCTION; SUBSTANCE WITHDRAWAL SYNDROME; SWIMMING;

EID: 38149044833     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.10.007     Document Type: Article

References (63)

1. Ambrose L.M., Gallaher S.M., Unterwald E.M., and Van Bockstaele E.J. Dopamine-D1 and delta-opioid receptors co-exist in rat striatum neurons. Neurosci. Lett. 399 (2006) 191-196
2. Azaryan A.V., Coughlin L.J., Buzas B., Clock B.J., and Cox B.M. Effect of chronic cocaine treatment on mu- and delta-opioid receptor mRNA levels in dopaminergically innervated brain regions. J. Neurochem. 66 (1996) 443-448
3. Baamonde A., Dauge V., Ruiz-Gayo M., Fulga I.G., Turcaud S., Fournie-Zaluski M.C., and Roques B.P. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation. Eur. J. Pharmacol. 216 (1992) 157-166
4. Basso A.M., Spina M., Rivier J., Vale W., and Koob G.F. Corticotropin-releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in the elevated plus-maze following chronic cocaine in rats. Psychopharmacology (Berl.) 145 (1999) 21-30
5. Baumann M.H., and Rothman R.B. Alterations in serotonergic responsiveness during cocaine withdrawal in rats: similarities to major depression in humans. Biol. Psychiatry 44 (1998) 578-591
6. Baumann M.H., Milchanowski A.B., and Rothman R.B. Evidence for alterations in alpha2-adrenergic receptor sensitivity in rats exposed to repeated cocaine administration. Neuroscience 125 (2004) 683-690
7. Blanchard D.C., and Blanchard R.J. Cocaine potentiates defensive behaviors related to fear and anxiety. Neurosci. Biobehav. Rev. 23 (1999) 981-991
8. Broom D.C., Jutkiewicz E.M., Folk J.E., Traynor J.R., Rice K.C., and Woods J.H. Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology 26 (2002) 744-755
9. Brown B.L., Albano J.D., Ekins R.P., and Sgherzi A.M. A simple and sensitive saturation assay method for the measurement of adenosine 3′:5′-cyclic monophosphate. Biochem. J. 121 (1971) 561-562
10. Detke M.J., Rickels M., and Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl.) 121 (1995) 66-72
11. Ettenberg A., and Geist T.D. Animal model for investigating the anxiogenic effects of self-administered cocaine. Psychopharmacology (Berl) 103 (1991) 455-461
12. Filliol D., Ghozland S., Chluba J., Martin M., Matthes H.W., Simonin F., Befort K., Gaveriaux-Ruff C., Dierich A., LeMeur M., Valverde O., Maldonado R., and Kieffer B.L. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat. Genet. 25 (2000) 195-200
13. Fink J.S., and Smith G.P. Mesolimbicocortical dopamine terminal fields are necessary for normal locomotor and investigatory exploration in rats. Brain Res. 199 (1980) 359-384
14. Gawin F.H. Cocaine addiction: psychology and neurophysiology. Science 251 (1991) 1580-1586
15. Hammer Jr. R.P. Cocaine alters opiate receptor binding in critical brain reward regions. Synapse 3 (1989) 55-60
16. Handley S.L., and McBlane J.W. An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J. Pharmacol. Toxicol. Methods 29 (1993) 129-138
17. Heikkila R.E., Orlansky H., and Cohen G. Studies on the distinction between uptake inhibition and release of (3H)dopamine in rat brain tissue slices. Biochem. Pharmacol. 24 (1975) 847-852
18. Hindmarch I. Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur. Psychiatry 17 Suppl. 3 (2002) 294-299
19. Holtzheimer III P.E., and Nemeroff C.B. Advances in the treatment of depression. NeuroRx 3 (2006) 42-56
20. Hoplight B.J., Vincow E.S., and Neumaier J.F. The effects of SB 224289 on anxiety and cocaine-related behaviors in a novel object task. Physiol. Behav. 84 (2005) 707-714
21. Hurd Y.L., Brown E.E., Finlay J.M., Fibiger H.C., and Gerfen C.R. Cocaine self-administration differentially alters mRNA expression of striatal peptides. Brain Res. Mol. Brain Res. 13 (1992) 165-170
22. Izenwasser S., Heller B., and Cox B.M. Continuous cocaine administration enhances mu- but not delta-opioid receptor-mediated inhibition of adenylyl cyclase activity in nucleus accumbens. Eur. J. Pharmacol. 297 (1996) 187-191
23. Jutkiewicz E.M., Rice K.C., Woods J.H., and Winsauer P.J. Effects of the delta-opioid receptor agonist SNC80 on learning relative to its antidepressant-like effects in rats. Behav. Pharmacol. 14 (2003) 509-516
24. Kosten T.R., Gawin F.H., Rounsaville B.J., and Kleber H.D. Cocaine abuse among opioid addicts: demographic and diagnostic factors in treatment. Am. J. Drug Alcohol Abuse 12 (1986) 1-16
25. Kreek M.J., Bor G.L., Zhou Y., and Schluger J. Relationship between endocrine functions and substance abuse syndromes: heroin and related short-acting opiates in addiction contrasted with methadone and other long-acting opioid agonists used in pharmacotherapy of addiction. In: Pfaff D. (Ed). Hormones, Brain and Behavior (2002), Academic Press, San Diego 781-830
26. Law P.Y., Hom D.S., and Loh H.H. Loss of opiate receptor activity in neuroblastoma X glioma NG108-15 hybrid cells after chronic opiate treatment. A multiple-step process. Mol. Pharmacol. 22 (1982) 1-4
27. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav. Pharmacol. 8 (1997) 523-532
28. Mackler S.A., and O'Brien C.P. Cocaine abuse. Adv. Intern. Med. 37 (1992) 21-35
29. Magalhaes A., Tavares M.A., and de Sousa L. Postnatal cocaine exposure: effects on behavior of rats in forced swim test. Ann. NY Acad. Sci. 965 (2002) 529-534
30. Mantsch J.R., Schlussman S.D., Ho A., and Kreek M.J. Effects of cocaine self-administration on plasma corticosterone and prolactin in rats. J. Pharmacol. Exp. Ther. 294 (2000) 239-247
31. Marin S., Marco E., Biscaia M., Fernandez B., Rubio M., Guaza C., Schmidhammer H., and Viveros M.P. Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol. Biochem. Behav. 74 (2003) 649-656
32. Markou A., and Koob G.F. Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 4 (1991) 17-26
33. Moleman P., van Valkenburg C.F., and vd Krogt J.A. Effects of morphine on dopamine metabolism in rat striatum and limbic structures in relation to the activity of dopaminergic neurones. Naunyn Schmiedebergs Arch. Pharmacol. 327 (1984) 208-213
34. Nieto M.M., Guen S.L., Kieffer B.L., Roques B.P., and Noble F. Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors. Neuroscience 135 (2005) 305-313
35. Nutt D.J. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 10 (2005) 49-56
36. Nutt D.J. The role of dopamine and norepinephrine in depression and antidepressant treatment. J. Clin. Psychiatry 67 Suppl. 6 (2006) 3-8
37. O'Brien C.P. Recent developments in the pharmacotherapy of substance abuse. J. Consult Clin. Psychol. 64 (1996) 677-686
38. Olive M.F., Koenig H.N., Nannini M.A., and Hodge C.W. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J. Neurosci. 21 (2001) RC184
39. Overstreet D.H., Moy S.S., Lubin D.A., Gause L.R., Lieberman J.A., and Johns J.M. Enduring effects of prenatal cocaine administration on emotional behavior in rats. Physiol. Behav. 70 (2000) 149-156
40. Paine T.A., Jackman S.L., and Olmstead M.C. Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine. Behav. Pharmacol. 13 (2002) 511-523
41. Pak Y., Kouvelas A., Scheideler M.A., Rasmussen J., O'Dowd B.F., and George S.R. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein. Mol. Pharmacol. 50 (1996) 1214-1222
42. Pellow S., Chopin P., File S.E., and Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14 (1985) 149-167
43. Perrine S.A., Hoshaw B.A., and Unterwald E.M. Delta opioid receptor ligands modulate anxiety-like behaviors in the rat. Br. J. Pharmacol. 147 (2006) 864-872
44. Pickel V.M., Chan J., and Sesack S.R. Cellular basis for interactions between catecholaminergic afferents and neurons containing Leu-enkephalin-like immunoreactivity in rat caudate-putamen nuclei. J. Neurosci. Res. 31 (1992) 212-230
45. Ritz M.C., Lamb R.J., Goldberg S.R., and Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237 (1987) 1219-1223
46. Roberts D.C., and Koob G.F. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacol. Biochem. Behav. 17 (1982) 901-904
47. Rogerio R., and Takahashi R.N. Anxiogenic properties of cocaine in the rat evaluated with the elevated plus-maze. Pharmacol. Biochem. Behav. 43 (1992) 631-633
48. Saitoh A., Kimura Y., Suzuki T., Kawai K., Nagase H., and Kamei J. Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J. Pharmacol. Sci. 95 (2004) 374-380
49. Saitoh A., Yoshikawa Y., Onodera K., and Kamei J. Role of delta-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats. Psychopharmacology (Berl) 182 (2005) 327-334
50. Sarkisova K.Y., Midzianovskaia I.S., and Kulikov M.A. Depressive-like behavioral alterations and c-fos expression in the dopaminergic brain regions in WAG/Rij rats with genetic absence epilepsy. Behav. Brain Res. 144 (2003) 211-226
51. Schmitz J.M., Averill P., Stotts A.L., Moeller F.G., Rhoades H.M., and Grabowski J. Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. Drug Alcohol Depend. 63 (2001) 207-214
52. Sivam S.P. Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism. J. Pharmacol. Exp. Ther. 250 (1989) 818-824
53. Sobrian S.K., Marr L., and Ressman K. Prenatal cocaine and/or nicotine exposure produces depression and anxiety in aging rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 501-518
54. Svingos A.L., Clarke C.L., and Pickel V.M. Cellular sites for activation of delta-opioid receptors in the rat nucleus accumbens shell: relationship with Met5-enkephalin. J. Neurosci. 18 (1998) 1923-1933
55. Svingos A.L., Clarke C.L., and Pickel V.M. Localization of the delta-opioid receptor and dopamine transporter in the nucleus accumbens shell: implications for opiate and psychostimulant cross-sensitization. Synapse 34 (1999) 1-10
56. Unterwald E.M., and Cuntapay M. Dopamine-opioid interactions in the rat striatum: a modulatory role for dopamine D1 receptors in delta opioid receptor-mediated signal transduction. Neuropharmacology 39 (2000) 372-381
57. Unterwald E.M., Cox B.M., Kreek M.J., Cote T.E., and Izenwasser S. Chronic repeated cocaine administration alters basal and opioid-regulated adenylyl cyclase activity. Synapse 15 (1993) 33-38
58. Unterwald E.M., Rubenfeld J.M., and Kreek M.J. Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport 5 (1994) 1613-1616
59. Willner P., Muscat R., and Papp M. Chronic mild stress-induced anhedonia: a realistic animal model of depression. Neurosci. Biobehav. Rev. 16 (1992) 525-534
60. Wood D.M., and Lal H. Anxiogenic properties of cocaine withdrawal. Life Sci. 41 (1987) 1431-1436
61. Yang X.M., Gorman A.L., Dunn A.J., and Goeders N.E. Anxiogenic effects of acute and chronic cocaine administration: neurochemical and behavioral studies. Pharmacol. Biochem. Behav. 41 (1992) 643-650
62. Zacharko R.M., and Anisman H. Stressor-induced anhedonia in the mesocorticolimbic system. Neurosci. Biobehav. Rev. 15 (1991) 391-405
63. Zhou Y., Spangler R., Schlussman S.D., Ho A., and Kreek M.J. Alterations in hypothalamic-pituitary-adrenal axis activity and in levels of proopiomelanocortin and corticotropin-releasing hormone-receptor 1 mRNAs in the pituitary and hypothalamus of the rat during chronic 'binge' cocaine and withdrawal. Brain Res. 964 (2003) 187-199